abstract: A rich Haitian ethnopsychology has been described, detailing concepts of personhood, explanatory models of illness, and links between mind and body. However, little research has engaged explicitly with @entity5 , and that which does focuses on the Krey  l term fou (madness), a term that psychiatrists associate with @entity2 and @entity4 . More work is needed to characterize potential forms of mild-to-moderate @entity5 . Idioms of distress provide a promising avenue for exploring common @entity1 . Working in @entity6 , we aimed to identify idioms of distress that represent cultural syndromes. We used ethnographic and epidemiologic methods to explore the idiom of distress reflechi tw  p (thinking too much). This syndrome is characterized by troubled rumination at the intersection of sadness, severe @entity1 , suicide, and social and structural hardship. @entity0 with "thinking too much" have greater scores on the Beck Depression Inventory and Beck Anxiety Inventory. "Thinking too much" is associated with 8 times greater odds of suicidal ideation. Untreated "thinking too much" is sometimes perceived to lead to @entity3 . Recognizing and understanding "thinking too much" may allow early clinical recognition and interventions to reduce long-term psychosocial suffering in @entity6 .

title: Reflechi tw  p--thinking too much: description of a cultural syndrome in XXXX .

answer: @entity6


abstract: The objective of this study was designed to test whether supplementation of the diet with @entity0 ( @entity1 ) or @entity2 ( @entity5 ) or their combination influences the production, organ weights and humoral immune response of broilers. A total of 432 one-day-old male Ross 308 broiler @entity3 were divided into 6 treatment groups: control, @entity1 -0.5%, @entity1 -1%, @entity5 -0.5%, @entity5 -1% and @entity1 -0.5%+ @entity5 -0.5%. Drinking water and feed were provided ad libitum. On day 18 of the experiment 50% of @entity3 in each treatment group were immunised with bovine serum albumin. Ten and 21 days after immunisation blood samples were collected to determine the anti-albumin IgY titre, @entity6 ( @entity6 ) and @entity7 ( @entity7 ) and to measure the weight of the liver, spleen, bursa of Fabricius and thymus. @entity1 or @entity5 supplementation of the diets influenced neither the production nor the organ weights until 18 days of age. Between 18 and 39 days of age both @entity1 (0.5% and 1%) and @entity1 + @entity5 supplementation improved the feed conversion ratio ( @entity4 ) by 3.7%, 6.3% and 4.9%, respectively, while @entity5 -1% worsened it by 15%. Immunisation slightly (-0.79%) depressed the body weight gain of broilers fed the control diet, which was significantly improved by both @entity1 (0.5 or 1%) and @entity1 + @entity5 supplementation. Immunisation increased the weight of the spleen, bursa and thymus and decreased that of the liver. Supplementation with 1% @entity5 depressed (-5.13%) the body weight gain of the immunised @entity3 but strongly stimulated the immune response. Supplementations with @entity1 and @entity5 did not influence the @entity6 and @entity7 level of the blood; however, on day 10 after immunisation these two parameters showed a negative correlation with each other. Regarding production, organ weights and immunity, @entity1 supplementation should be recommended in the grower phase, while @entity5 supplementation can be useful in pullets raised for egg production, where a good immune response to vaccinations is an important factor.

title: Effect of @entity0 or @entity2 supplementation on production, organ weights, XXXX , @entity6 and antibody titre of broilers.

answer: @entity7


abstract: The objective of this study was designed to test whether supplementation of the diet with @entity0 ( @entity1 ) or @entity2 ( @entity5 ) or their combination influences the production, organ weights and humoral immune response of broilers. A total of 432 one-day-old male Ross 308 broiler @entity3 were divided into 6 treatment groups: control, @entity1 -0.5%, @entity1 -1%, @entity5 -0.5%, @entity5 -1% and @entity1 -0.5%+ @entity5 -0.5%. Drinking water and feed were provided ad libitum. On day 18 of the experiment 50% of @entity3 in each treatment group were immunised with bovine serum albumin. Ten and 21 days after immunisation blood samples were collected to determine the anti-albumin IgY titre, @entity6 ( @entity6 ) and @entity7 ( @entity7 ) and to measure the weight of the liver, spleen, bursa of Fabricius and thymus. @entity1 or @entity5 supplementation of the diets influenced neither the production nor the organ weights until 18 days of age. Between 18 and 39 days of age both @entity1 (0.5% and 1%) and @entity1 + @entity5 supplementation improved the feed conversion ratio ( @entity4 ) by 3.7%, 6.3% and 4.9%, respectively, while @entity5 -1% worsened it by 15%. Immunisation slightly (-0.79%) depressed the body weight gain of broilers fed the control diet, which was significantly improved by both @entity1 (0.5 or 1%) and @entity1 + @entity5 supplementation. Immunisation increased the weight of the spleen, bursa and thymus and decreased that of the liver. Supplementation with 1% @entity5 depressed (-5.13%) the body weight gain of the immunised @entity3 but strongly stimulated the immune response. Supplementations with @entity1 and @entity5 did not influence the @entity6 and @entity7 level of the blood; however, on day 10 after immunisation these two parameters showed a negative correlation with each other. Regarding production, organ weights and immunity, @entity1 supplementation should be recommended in the grower phase, while @entity5 supplementation can be useful in pullets raised for egg production, where a good immune response to vaccinations is an important factor.

title: Effect of @entity0 or @entity2 supplementation on production, organ weights, @entity7 , XXXX and antibody titre of broilers.

answer: @entity6


abstract: The objective of this study was designed to test whether supplementation of the diet with @entity0 ( @entity1 ) or @entity2 ( @entity5 ) or their combination influences the production, organ weights and humoral immune response of broilers. A total of 432 one-day-old male Ross 308 broiler @entity3 were divided into 6 treatment groups: control, @entity1 -0.5%, @entity1 -1%, @entity5 -0.5%, @entity5 -1% and @entity1 -0.5%+ @entity5 -0.5%. Drinking water and feed were provided ad libitum. On day 18 of the experiment 50% of @entity3 in each treatment group were immunised with bovine serum albumin. Ten and 21 days after immunisation blood samples were collected to determine the anti-albumin IgY titre, @entity6 ( @entity6 ) and @entity7 ( @entity7 ) and to measure the weight of the liver, spleen, bursa of Fabricius and thymus. @entity1 or @entity5 supplementation of the diets influenced neither the production nor the organ weights until 18 days of age. Between 18 and 39 days of age both @entity1 (0.5% and 1%) and @entity1 + @entity5 supplementation improved the feed conversion ratio ( @entity4 ) by 3.7%, 6.3% and 4.9%, respectively, while @entity5 -1% worsened it by 15%. Immunisation slightly (-0.79%) depressed the body weight gain of broilers fed the control diet, which was significantly improved by both @entity1 (0.5 or 1%) and @entity1 + @entity5 supplementation. Immunisation increased the weight of the spleen, bursa and thymus and decreased that of the liver. Supplementation with 1% @entity5 depressed (-5.13%) the body weight gain of the immunised @entity3 but strongly stimulated the immune response. Supplementations with @entity1 and @entity5 did not influence the @entity6 and @entity7 level of the blood; however, on day 10 after immunisation these two parameters showed a negative correlation with each other. Regarding production, organ weights and immunity, @entity1 supplementation should be recommended in the grower phase, while @entity5 supplementation can be useful in pullets raised for egg production, where a good immune response to vaccinations is an important factor.

title: Effect of @entity0 or XXXX supplementation on production, organ weights, @entity7 , @entity6 and antibody titre of broilers.

answer: @entity2


abstract: The objective of this study was designed to test whether supplementation of the diet with @entity0 ( @entity1 ) or @entity2 ( @entity5 ) or their combination influences the production, organ weights and humoral immune response of broilers. A total of 432 one-day-old male Ross 308 broiler @entity3 were divided into 6 treatment groups: control, @entity1 -0.5%, @entity1 -1%, @entity5 -0.5%, @entity5 -1% and @entity1 -0.5%+ @entity5 -0.5%. Drinking water and feed were provided ad libitum. On day 18 of the experiment 50% of @entity3 in each treatment group were immunised with bovine serum albumin. Ten and 21 days after immunisation blood samples were collected to determine the anti-albumin IgY titre, @entity6 ( @entity6 ) and @entity7 ( @entity7 ) and to measure the weight of the liver, spleen, bursa of Fabricius and thymus. @entity1 or @entity5 supplementation of the diets influenced neither the production nor the organ weights until 18 days of age. Between 18 and 39 days of age both @entity1 (0.5% and 1%) and @entity1 + @entity5 supplementation improved the feed conversion ratio ( @entity4 ) by 3.7%, 6.3% and 4.9%, respectively, while @entity5 -1% worsened it by 15%. Immunisation slightly (-0.79%) depressed the body weight gain of broilers fed the control diet, which was significantly improved by both @entity1 (0.5 or 1%) and @entity1 + @entity5 supplementation. Immunisation increased the weight of the spleen, bursa and thymus and decreased that of the liver. Supplementation with 1% @entity5 depressed (-5.13%) the body weight gain of the immunised @entity3 but strongly stimulated the immune response. Supplementations with @entity1 and @entity5 did not influence the @entity6 and @entity7 level of the blood; however, on day 10 after immunisation these two parameters showed a negative correlation with each other. Regarding production, organ weights and immunity, @entity1 supplementation should be recommended in the grower phase, while @entity5 supplementation can be useful in pullets raised for egg production, where a good immune response to vaccinations is an important factor.

title: Effect of XXXX or @entity2 supplementation on production, organ weights, @entity7 , @entity6 and antibody titre of broilers.

answer: @entity0


abstract: Anogenital warts are caused by @entity1 ), over 30 types of which are infectious for the anogenital tract. Without treatment, warts may regress spontaneously, remain unchanged, or increase in number and size. This study compared the efficacy of a topical 5% @entity5 ( @entity3 ) solution with that of a topical 0.5% @entity2 ( @entity2 ) and 10% @entity4 (SA) combination in the treatment of @entity6 . Sixty @entity0 were randomly assigned to receive topical @entity3 or @entity2  +  SA. Both groups demonstrated a significant decrease in numbers of lesions (P  <  0.05), but this difference was not significant at week 12 (P  >  0.05). The mean number of lesions decreased from baseline to week 12 from 17.03      12.64 to 3.73      7.30 and from 16.13      12.97 to 3.10      4.90 in the @entity3 and @entity2  +  SA groups, respectively (P  <  0.001). Excellent clearance was achieved by 70.0 and 76.7% of @entity0 in the @entity3 and @entity2  +  SA groups, respectively. Marked improvement was seen in 13.3 and 20.0% of @entity0 in the @entity3 and @entity2  +  SA groups, respectively. At week 16, relapse was observed in two @entity0 in the @entity3 group and three in the @entity2  +  SA group (P  >  0.05). No serious adverse events were reported. Neither treatment was more efficacious. Safety and ease of application are important goals in treatments for @entity6 . A 5% @entity3 solution is a promising alternative treatment because it is effective and inexpensive and causes minimal side effects.

title: A comparison of a 5% @entity5 solution with a @entity2 and XXXX combination in the treatment of @entity0 with @entity6 : a randomized, open-label clinical trial.

answer: @entity4


abstract: Anogenital warts are caused by @entity1 ), over 30 types of which are infectious for the anogenital tract. Without treatment, warts may regress spontaneously, remain unchanged, or increase in number and size. This study compared the efficacy of a topical 5% @entity5 ( @entity3 ) solution with that of a topical 0.5% @entity2 ( @entity2 ) and 10% @entity4 (SA) combination in the treatment of @entity6 . Sixty @entity0 were randomly assigned to receive topical @entity3 or @entity2  +  SA. Both groups demonstrated a significant decrease in numbers of lesions (P  <  0.05), but this difference was not significant at week 12 (P  >  0.05). The mean number of lesions decreased from baseline to week 12 from 17.03      12.64 to 3.73      7.30 and from 16.13      12.97 to 3.10      4.90 in the @entity3 and @entity2  +  SA groups, respectively (P  <  0.001). Excellent clearance was achieved by 70.0 and 76.7% of @entity0 in the @entity3 and @entity2  +  SA groups, respectively. Marked improvement was seen in 13.3 and 20.0% of @entity0 in the @entity3 and @entity2  +  SA groups, respectively. At week 16, relapse was observed in two @entity0 in the @entity3 group and three in the @entity2  +  SA group (P  >  0.05). No serious adverse events were reported. Neither treatment was more efficacious. Safety and ease of application are important goals in treatments for @entity6 . A 5% @entity3 solution is a promising alternative treatment because it is effective and inexpensive and causes minimal side effects.

title: A comparison of a 5% @entity5 solution with a @entity2 and @entity4 combination in the treatment of @entity0 with XXXX : a randomized, open-label clinical trial.

answer: @entity6


abstract: Anogenital warts are caused by @entity1 ), over 30 types of which are infectious for the anogenital tract. Without treatment, warts may regress spontaneously, remain unchanged, or increase in number and size. This study compared the efficacy of a topical 5% @entity5 ( @entity3 ) solution with that of a topical 0.5% @entity2 ( @entity2 ) and 10% @entity4 (SA) combination in the treatment of @entity6 . Sixty @entity0 were randomly assigned to receive topical @entity3 or @entity2  +  SA. Both groups demonstrated a significant decrease in numbers of lesions (P  <  0.05), but this difference was not significant at week 12 (P  >  0.05). The mean number of lesions decreased from baseline to week 12 from 17.03      12.64 to 3.73      7.30 and from 16.13      12.97 to 3.10      4.90 in the @entity3 and @entity2  +  SA groups, respectively (P  <  0.001). Excellent clearance was achieved by 70.0 and 76.7% of @entity0 in the @entity3 and @entity2  +  SA groups, respectively. Marked improvement was seen in 13.3 and 20.0% of @entity0 in the @entity3 and @entity2  +  SA groups, respectively. At week 16, relapse was observed in two @entity0 in the @entity3 group and three in the @entity2  +  SA group (P  >  0.05). No serious adverse events were reported. Neither treatment was more efficacious. Safety and ease of application are important goals in treatments for @entity6 . A 5% @entity3 solution is a promising alternative treatment because it is effective and inexpensive and causes minimal side effects.

title: A comparison of a 5% @entity5 solution with a XXXX and @entity4 combination in the treatment of @entity0 with @entity6 : a randomized, open-label clinical trial.

answer: @entity2


abstract: Anogenital warts are caused by @entity1 ), over 30 types of which are infectious for the anogenital tract. Without treatment, warts may regress spontaneously, remain unchanged, or increase in number and size. This study compared the efficacy of a topical 5% @entity5 ( @entity3 ) solution with that of a topical 0.5% @entity2 ( @entity2 ) and 10% @entity4 (SA) combination in the treatment of @entity6 . Sixty @entity0 were randomly assigned to receive topical @entity3 or @entity2  +  SA. Both groups demonstrated a significant decrease in numbers of lesions (P  <  0.05), but this difference was not significant at week 12 (P  >  0.05). The mean number of lesions decreased from baseline to week 12 from 17.03      12.64 to 3.73      7.30 and from 16.13      12.97 to 3.10      4.90 in the @entity3 and @entity2  +  SA groups, respectively (P  <  0.001). Excellent clearance was achieved by 70.0 and 76.7% of @entity0 in the @entity3 and @entity2  +  SA groups, respectively. Marked improvement was seen in 13.3 and 20.0% of @entity0 in the @entity3 and @entity2  +  SA groups, respectively. At week 16, relapse was observed in two @entity0 in the @entity3 group and three in the @entity2  +  SA group (P  >  0.05). No serious adverse events were reported. Neither treatment was more efficacious. Safety and ease of application are important goals in treatments for @entity6 . A 5% @entity3 solution is a promising alternative treatment because it is effective and inexpensive and causes minimal side effects.

title: A comparison of a 5% XXXX solution with a @entity2 and @entity4 combination in the treatment of @entity0 with @entity6 : a randomized, open-label clinical trial.

answer: @entity5


abstract: Anogenital warts are caused by @entity1 ), over 30 types of which are infectious for the anogenital tract. Without treatment, warts may regress spontaneously, remain unchanged, or increase in number and size. This study compared the efficacy of a topical 5% @entity5 ( @entity3 ) solution with that of a topical 0.5% @entity2 ( @entity2 ) and 10% @entity4 (SA) combination in the treatment of @entity6 . Sixty @entity0 were randomly assigned to receive topical @entity3 or @entity2  +  SA. Both groups demonstrated a significant decrease in numbers of lesions (P  <  0.05), but this difference was not significant at week 12 (P  >  0.05). The mean number of lesions decreased from baseline to week 12 from 17.03      12.64 to 3.73      7.30 and from 16.13      12.97 to 3.10      4.90 in the @entity3 and @entity2  +  SA groups, respectively (P  <  0.001). Excellent clearance was achieved by 70.0 and 76.7% of @entity0 in the @entity3 and @entity2  +  SA groups, respectively. Marked improvement was seen in 13.3 and 20.0% of @entity0 in the @entity3 and @entity2  +  SA groups, respectively. At week 16, relapse was observed in two @entity0 in the @entity3 group and three in the @entity2  +  SA group (P  >  0.05). No serious adverse events were reported. Neither treatment was more efficacious. Safety and ease of application are important goals in treatments for @entity6 . A 5% @entity3 solution is a promising alternative treatment because it is effective and inexpensive and causes minimal side effects.

title: A comparison of a 5% @entity5 solution with a @entity2 and @entity4 combination in the treatment of XXXX with @entity6 : a randomized, open-label clinical trial.

answer: @entity0


abstract: PURPOSE: Targeted therapy (TT) provides highly effective @entity1 treatment for appropriately selected individuals. A major challenge of TT is to select @entity0 who would benefit most. EXPERIMENTAL DESIGN: The study uses @entity1 material from 25 @entity0 primarily diagnosed with @entity2 ( @entity2 ). @entity0 -derived xenografts (PDXs) are treated with cetuximab and @entity3 . Treatment response is measured by @entity1 shrinkage comparing @entity1 volume at day 25 (V25) with @entity1 volume at baseline (V0). Shrinkage below 40% is considered as treatment response: V25/V0 < 0.4 (<40%). Furthermore, RNA-seq data from each @entity1 sample are used to predict @entity1 response to either treatment using an in silico molecular signaling map (MSM) approach. RESULTS: PDX response was 40% (10/25; 95% CI [21.13%, 61.34%]) under cetuximab and 20% (5/25; 95% CI [6.83%, 40.70%]) under @entity3 . MSM predicted response was 48% (12/25; 95% CI [27.8%, 68.7%]) under cetuximab and 40% (10/25; 95% CI [21.13%, 61.34%]) under @entity3 . Agreement between PDX and MSM response prediction is substantial under cetuximab and @entity3 : 84% (21/25, P = 0.001) and 80% (20/25, P = 0.003). A total of 5 from the 25 @entity0 have been treated with cetuximab showing a clinical response identical to both predictions. CONCLUSIONS: For @entity2 @entity0 , this proof-of-concept study shows a considerable agreement in response prediction from MSM and PDX approaches, but MSM saves time and laboratory resources. Our result indicates the potential of MSM-based approach for clinical decision making when selecting @entity1 TTs. Clin Cancer Res; 22(9); 2167-76.   2015 AACR.

title: Comparing XXXX -Derived Xenograft and Computational Response Prediction for Targeted Therapy in @entity0 of Early-Stage Large Cell Lung Cancer.

answer: @entity0


abstract: PURPOSE: Targeted therapy (TT) provides highly effective @entity1 treatment for appropriately selected individuals. A major challenge of TT is to select @entity0 who would benefit most. EXPERIMENTAL DESIGN: The study uses @entity1 material from 25 @entity0 primarily diagnosed with @entity2 ( @entity2 ). @entity0 -derived xenografts (PDXs) are treated with cetuximab and @entity3 . Treatment response is measured by @entity1 shrinkage comparing @entity1 volume at day 25 (V25) with @entity1 volume at baseline (V0). Shrinkage below 40% is considered as treatment response: V25/V0 < 0.4 (<40%). Furthermore, RNA-seq data from each @entity1 sample are used to predict @entity1 response to either treatment using an in silico molecular signaling map (MSM) approach. RESULTS: PDX response was 40% (10/25; 95% CI [21.13%, 61.34%]) under cetuximab and 20% (5/25; 95% CI [6.83%, 40.70%]) under @entity3 . MSM predicted response was 48% (12/25; 95% CI [27.8%, 68.7%]) under cetuximab and 40% (10/25; 95% CI [21.13%, 61.34%]) under @entity3 . Agreement between PDX and MSM response prediction is substantial under cetuximab and @entity3 : 84% (21/25, P = 0.001) and 80% (20/25, P = 0.003). A total of 5 from the 25 @entity0 have been treated with cetuximab showing a clinical response identical to both predictions. CONCLUSIONS: For @entity2 @entity0 , this proof-of-concept study shows a considerable agreement in response prediction from MSM and PDX approaches, but MSM saves time and laboratory resources. Our result indicates the potential of MSM-based approach for clinical decision making when selecting @entity1 TTs. Clin Cancer Res; 22(9); 2167-76.   2015 AACR.

title: Comparing @entity0 -Derived Xenograft and Computational Response Prediction for Targeted Therapy in XXXX of Early-Stage Large Cell Lung Cancer.

answer: @entity0


abstract: BACKGROUND: In @entity4 ( @entity4 ) @entity0 : (i) To compare the ability of a multiparametric MRI (mpMRI)-ultrasound biopsy system to detect clinically significant (CS) @entity2 with systematic 12-core biopsy (R-TRUSBx), and (ii) To assess the predictive value of mpMRI with biopsy as the reference standard. METHODS: Seventy-two @entity0 on @entity4 prospectively underwent 3T mpMRI . MRI-ultrasound fusion biopsy (UroNavBx) and R-TRUSBx was performed. @entity1 was defined using two thresholds: 1) @entity3   >=    7 (CS7) and 2) @entity3   =   6 with >50% involvement (GS6). @entity1 detection rates and predictive values were determined. RESULTS: CS7 @entity1 were found in 19/72 (26%), 7 (37%) identified by UroNavBx alone, 2 (11%) by R-TRUSBx alone (P   =   0.182). UroNav targeted biopsy was 6.3  more likely to yield a core positive for CS7 @entity1 compared with R-TRUSBx (25% of 141 versus 4% of 874, P   <   0.001). Upgrading of @entity3 occurred in 15/72 @entity0 (21%), 13 (87%) detected by UroNavBx and 10 (67%) by R-TRUSBx. The NPV of mpMRI for CS7 @entity1 was 100%. MRI suspicion level significantly predicted @entity1 on multivariate analysis (OR 3.6, P   <   0.001). CONCLUSION: UroNavBx detected @entity1 with far fewer cores compared with R-TRUSBx, and mpMRI had a perfect negative predictive value in this population. J. Magn. Reson. Imaging 2014.    2014 Wiley Periodicals, Inc.

title: A prospective comparison of MRI-US fused targeted biopsy versus systematic ultrasound-guided biopsy for detecting clinically significant XXXX in @entity0 on @entity4 .

answer: @entity2


abstract: BACKGROUND: In @entity4 ( @entity4 ) @entity0 : (i) To compare the ability of a multiparametric MRI (mpMRI)-ultrasound biopsy system to detect clinically significant (CS) @entity2 with systematic 12-core biopsy (R-TRUSBx), and (ii) To assess the predictive value of mpMRI with biopsy as the reference standard. METHODS: Seventy-two @entity0 on @entity4 prospectively underwent 3T mpMRI . MRI-ultrasound fusion biopsy (UroNavBx) and R-TRUSBx was performed. @entity1 was defined using two thresholds: 1) @entity3   >=    7 (CS7) and 2) @entity3   =   6 with >50% involvement (GS6). @entity1 detection rates and predictive values were determined. RESULTS: CS7 @entity1 were found in 19/72 (26%), 7 (37%) identified by UroNavBx alone, 2 (11%) by R-TRUSBx alone (P   =   0.182). UroNav targeted biopsy was 6.3  more likely to yield a core positive for CS7 @entity1 compared with R-TRUSBx (25% of 141 versus 4% of 874, P   <   0.001). Upgrading of @entity3 occurred in 15/72 @entity0 (21%), 13 (87%) detected by UroNavBx and 10 (67%) by R-TRUSBx. The NPV of mpMRI for CS7 @entity1 was 100%. MRI suspicion level significantly predicted @entity1 on multivariate analysis (OR 3.6, P   <   0.001). CONCLUSION: UroNavBx detected @entity1 with far fewer cores compared with R-TRUSBx, and mpMRI had a perfect negative predictive value in this population. J. Magn. Reson. Imaging 2014.    2014 Wiley Periodicals, Inc.

title: A prospective comparison of MRI-US fused targeted biopsy versus systematic ultrasound-guided biopsy for detecting clinically significant @entity2 in @entity0 on XXXX .

answer: @entity4


abstract: BACKGROUND: In @entity4 ( @entity4 ) @entity0 : (i) To compare the ability of a multiparametric MRI (mpMRI)-ultrasound biopsy system to detect clinically significant (CS) @entity2 with systematic 12-core biopsy (R-TRUSBx), and (ii) To assess the predictive value of mpMRI with biopsy as the reference standard. METHODS: Seventy-two @entity0 on @entity4 prospectively underwent 3T mpMRI . MRI-ultrasound fusion biopsy (UroNavBx) and R-TRUSBx was performed. @entity1 was defined using two thresholds: 1) @entity3   >=    7 (CS7) and 2) @entity3   =   6 with >50% involvement (GS6). @entity1 detection rates and predictive values were determined. RESULTS: CS7 @entity1 were found in 19/72 (26%), 7 (37%) identified by UroNavBx alone, 2 (11%) by R-TRUSBx alone (P   =   0.182). UroNav targeted biopsy was 6.3  more likely to yield a core positive for CS7 @entity1 compared with R-TRUSBx (25% of 141 versus 4% of 874, P   <   0.001). Upgrading of @entity3 occurred in 15/72 @entity0 (21%), 13 (87%) detected by UroNavBx and 10 (67%) by R-TRUSBx. The NPV of mpMRI for CS7 @entity1 was 100%. MRI suspicion level significantly predicted @entity1 on multivariate analysis (OR 3.6, P   <   0.001). CONCLUSION: UroNavBx detected @entity1 with far fewer cores compared with R-TRUSBx, and mpMRI had a perfect negative predictive value in this population. J. Magn. Reson. Imaging 2014.    2014 Wiley Periodicals, Inc.

title: A prospective comparison of MRI-US fused targeted biopsy versus systematic ultrasound-guided biopsy for detecting clinically significant @entity2 in XXXX on @entity4 .

answer: @entity0


abstract: Childhood stress and genetic factors like the @entity7 polymorphism of the @entity4 ( @entity4 ) gene are associated with a higher risk for developing @entity2 ( @entity2 ) and might also influence hippocampal changes. The aim of this study was to determine which hippocampal dentate gyrus and cornu ammonis subfields are altered in @entity2 compared to healthy controls and which subfields are affected by the @entity4 @entity7 polymorphism and @entity0 adversity. Adult @entity0 with @entity2 and healthy matched controls underwent high-resolution magnetic resonance imaging. Automatic segmentation using the programme FreeSurfer was used to segment the hippocampal subfields dentate gyrus (DG/ @entity6 ), @entity3 and @entity9 . The history of possible childhood adversity was assessed using the Childhood @entity1 Questionnaire and the @entity7 @entity4 SNP ( @entity8 ) genotypes were obtained. @entity0 with @entity2 had significantly smaller @entity6 /DG and @entity9 volumes compared to healthy controls. Furthermore, there was a significant interactive effect of @entity4 allele and childhood adversity on @entity9 and @entity6 /DG volumes. Met allele carriers without childhood adversity had larger and with childhood adversity smaller @entity6 /DG and @entity9 volumes than @entity5 -allele homozygotes. Our results highlight stress by gene interactions as relevant for hippocampal volume reductions, in particular for the subfield @entity9 and dentate gyrus. Hum Brain Mapp 35:5776-5783, 2014.    2014 Wiley Periodicals, Inc.

title: XXXX @entity7 genotype interacts with childhood adversity and influences the formation of hippocampal subfields.

answer: @entity4


abstract: Childhood stress and genetic factors like the @entity7 polymorphism of the @entity4 ( @entity4 ) gene are associated with a higher risk for developing @entity2 ( @entity2 ) and might also influence hippocampal changes. The aim of this study was to determine which hippocampal dentate gyrus and cornu ammonis subfields are altered in @entity2 compared to healthy controls and which subfields are affected by the @entity4 @entity7 polymorphism and @entity0 adversity. Adult @entity0 with @entity2 and healthy matched controls underwent high-resolution magnetic resonance imaging. Automatic segmentation using the programme FreeSurfer was used to segment the hippocampal subfields dentate gyrus (DG/ @entity6 ), @entity3 and @entity9 . The history of possible childhood adversity was assessed using the Childhood @entity1 Questionnaire and the @entity7 @entity4 SNP ( @entity8 ) genotypes were obtained. @entity0 with @entity2 had significantly smaller @entity6 /DG and @entity9 volumes compared to healthy controls. Furthermore, there was a significant interactive effect of @entity4 allele and childhood adversity on @entity9 and @entity6 /DG volumes. Met allele carriers without childhood adversity had larger and with childhood adversity smaller @entity6 /DG and @entity9 volumes than @entity5 -allele homozygotes. Our results highlight stress by gene interactions as relevant for hippocampal volume reductions, in particular for the subfield @entity9 and dentate gyrus. Hum Brain Mapp 35:5776-5783, 2014.    2014 Wiley Periodicals, Inc.

title: @entity4 XXXX genotype interacts with childhood adversity and influences the formation of hippocampal subfields.

answer: @entity7


abstract: The brainstem and basal ganglia are important in the pathophysiology of @entity1 ( @entity1 ). Reliable and sensitive detection of neural activity changes in these regions should be helpful in scientific and clinical research on @entity1 . In this study, we used resting state functional MRI and @entity5 ( @entity5 ) methods to examine spontaneous neural activity in 109 @entity0 with @entity1 . We examined activity in two frequency bands, slow-4 (between 0.027 and 0.073 Hz) and slow-5 (0.010-0.027 Hz). @entity0 had decreased @entity5 in the striatum and increased @entity5 in the midbrain, and changes were more significant in slow-4. Additionally, changes in slow-4 in both basal ganglia and midbrain correlated with the severity of the @entity2 . The @entity5 in the caudate nucleus positively correlated with the dose of @entity4 , while the @entity5 in the putamen negatively correlated with the disease duration in both slow-4 and slow-5 bands. In addition, the @entity5 in the rostral supplementary motor area negatively correlated with @entity3 subscale scores. Our findings show that with a large cohort of @entity0 and distinguishing frequency bands, neural modulations in the brainstem and striatum in @entity1 can be detected and may have clinical relevance. The physiological interpretation of these changes needs to be determined.

title: Frequency-dependent neural activity in XXXX .

answer: @entity1


abstract: PURPOSE: @entity4 ( @entity4 ) affects one third of @entity0 with @entity1 . Radiotherapy remains the gold-standard treatment; however, laboratory and clinical work suggest that @entity5 may be useful in treating @entity4 . The aim of this study was to examine @entity5 in @entity0 with @entity4 receiving radiotherapy. @entity0 AND METHODS: A multicenter, double-blind randomized trial of @entity5 versus placebo was conducted. Eligible @entity0 were age >=  18 years, had radiologically proven bone metastases, were scheduled to receive radiotherapy, and had @entity3 scores >=  4 of 10 (on 0-to-10 numeric rating scale). Before radiotherapy, baseline assessments were completed, followed by random assignment. Doses of @entity5 and placebo were increased over 4 weeks. The primary end point was treatment response, defined as a reduction of >=  2 points in worst @entity3 by week 4, accompanied by a stable or reduced opioid dose, compared with baseline. Secondary end points assessed average @entity3 , interference of @entity3 with activity, @entity3 , mood, quality of life, and adverse events. RESULTS: A total of 233 @entity0 were randomly assigned: 117 to placebo and 116 to @entity5 . The most common @entity1 were prostate (n = 88; 38%), breast (n = 77; 33%), and lung (n = 42; 18%). In the @entity5 arm, 45 @entity0 (38.8%) achieved the primary end point, compared with 47 (40.2%) in the placebo arm (adjusted odds ratio, 1.07; 95% CI, 0.63 to 1.81; P = .816). There were no statistically significant differences in average @entity3 , @entity3 interference, or quality of life between arms. There were differences in mood (P = .031) and @entity3 duration (P = .037) between arms. Outcomes were compared at 4 weeks. CONCLUSION: Our findings do not support the role of @entity5 in @entity0 with @entity4 receiving radiotherapy. The role of @entity5 in @entity4 with a clinical @entity2 component is unknown.

title: Randomized Double-Blind Trial of XXXX Versus Placebo in Conjunction With Palliative Radiotherapy for @entity4 .

answer: @entity5


abstract: PURPOSE: @entity4 ( @entity4 ) affects one third of @entity0 with @entity1 . Radiotherapy remains the gold-standard treatment; however, laboratory and clinical work suggest that @entity5 may be useful in treating @entity4 . The aim of this study was to examine @entity5 in @entity0 with @entity4 receiving radiotherapy. @entity0 AND METHODS: A multicenter, double-blind randomized trial of @entity5 versus placebo was conducted. Eligible @entity0 were age >=  18 years, had radiologically proven bone metastases, were scheduled to receive radiotherapy, and had @entity3 scores >=  4 of 10 (on 0-to-10 numeric rating scale). Before radiotherapy, baseline assessments were completed, followed by random assignment. Doses of @entity5 and placebo were increased over 4 weeks. The primary end point was treatment response, defined as a reduction of >=  2 points in worst @entity3 by week 4, accompanied by a stable or reduced opioid dose, compared with baseline. Secondary end points assessed average @entity3 , interference of @entity3 with activity, @entity3 , mood, quality of life, and adverse events. RESULTS: A total of 233 @entity0 were randomly assigned: 117 to placebo and 116 to @entity5 . The most common @entity1 were prostate (n = 88; 38%), breast (n = 77; 33%), and lung (n = 42; 18%). In the @entity5 arm, 45 @entity0 (38.8%) achieved the primary end point, compared with 47 (40.2%) in the placebo arm (adjusted odds ratio, 1.07; 95% CI, 0.63 to 1.81; P = .816). There were no statistically significant differences in average @entity3 , @entity3 interference, or quality of life between arms. There were differences in mood (P = .031) and @entity3 duration (P = .037) between arms. Outcomes were compared at 4 weeks. CONCLUSION: Our findings do not support the role of @entity5 in @entity0 with @entity4 receiving radiotherapy. The role of @entity5 in @entity4 with a clinical @entity2 component is unknown.

title: Randomized Double-Blind Trial of @entity5 Versus Placebo in Conjunction With Palliative Radiotherapy for XXXX .

answer: @entity4


abstract: OBJECTIVE: To compare the efficacy of @entity4 plus @entity5 (MA) with that of MA alone for treating @entity3 ( @entity3 ). METHODS: This pilot study included 16 @entity3 @entity0 who met at least one @entity2 ( @entity2 ) criterion and received either adjunctive @entity4 plus MA (MET group) or MA monotherapy (MA group). Each @entity0 in the MA group received 160 mg of MA daily, whereas @entity0 in the MET group received the same dose of MA plus 0.5 g of @entity4 thrice daily. Treatment response was assessed by histological examination of dilation and curettage specimens obtained after 12 weeks of therapy. RESULTS: Each group had eight @entity0 , and half of the @entity0 in each group were diagnosed with @entity2 . The complete response (CR) rate was 75% (6/8) in the MET group and 25% (2/8) in the MA group (p=0.105). Complications of @entity2 did not affect the response rates in either group. In the MET group, 75% (3/4) of the @entity0 had CR in the presence or absence of @entity2 . In the MA group, 50% (2/4) of the @entity0 with @entity2 had CR, whereas no @entity0 without @entity2 had CR. No irreversible @entity1 were observed. CONCLUSION: @entity4 plus MA may be a potential alternative therapy for treating @entity3 , and the @entity2 status of @entity0 may have no effect on the efficacy of @entity4 plus MA therapy.

title: Conservative therapy with @entity4 plus @entity5 for XXXX .

answer: @entity3


abstract: OBJECTIVE: To compare the efficacy of @entity4 plus @entity5 (MA) with that of MA alone for treating @entity3 ( @entity3 ). METHODS: This pilot study included 16 @entity3 @entity0 who met at least one @entity2 ( @entity2 ) criterion and received either adjunctive @entity4 plus MA (MET group) or MA monotherapy (MA group). Each @entity0 in the MA group received 160 mg of MA daily, whereas @entity0 in the MET group received the same dose of MA plus 0.5 g of @entity4 thrice daily. Treatment response was assessed by histological examination of dilation and curettage specimens obtained after 12 weeks of therapy. RESULTS: Each group had eight @entity0 , and half of the @entity0 in each group were diagnosed with @entity2 . The complete response (CR) rate was 75% (6/8) in the MET group and 25% (2/8) in the MA group (p=0.105). Complications of @entity2 did not affect the response rates in either group. In the MET group, 75% (3/4) of the @entity0 had CR in the presence or absence of @entity2 . In the MA group, 50% (2/4) of the @entity0 with @entity2 had CR, whereas no @entity0 without @entity2 had CR. No irreversible @entity1 were observed. CONCLUSION: @entity4 plus MA may be a potential alternative therapy for treating @entity3 , and the @entity2 status of @entity0 may have no effect on the efficacy of @entity4 plus MA therapy.

title: Conservative therapy with @entity4 plus XXXX for @entity3 .

answer: @entity5


abstract: OBJECTIVE: To compare the efficacy of @entity4 plus @entity5 (MA) with that of MA alone for treating @entity3 ( @entity3 ). METHODS: This pilot study included 16 @entity3 @entity0 who met at least one @entity2 ( @entity2 ) criterion and received either adjunctive @entity4 plus MA (MET group) or MA monotherapy (MA group). Each @entity0 in the MA group received 160 mg of MA daily, whereas @entity0 in the MET group received the same dose of MA plus 0.5 g of @entity4 thrice daily. Treatment response was assessed by histological examination of dilation and curettage specimens obtained after 12 weeks of therapy. RESULTS: Each group had eight @entity0 , and half of the @entity0 in each group were diagnosed with @entity2 . The complete response (CR) rate was 75% (6/8) in the MET group and 25% (2/8) in the MA group (p=0.105). Complications of @entity2 did not affect the response rates in either group. In the MET group, 75% (3/4) of the @entity0 had CR in the presence or absence of @entity2 . In the MA group, 50% (2/4) of the @entity0 with @entity2 had CR, whereas no @entity0 without @entity2 had CR. No irreversible @entity1 were observed. CONCLUSION: @entity4 plus MA may be a potential alternative therapy for treating @entity3 , and the @entity2 status of @entity0 may have no effect on the efficacy of @entity4 plus MA therapy.

title: Conservative therapy with XXXX plus @entity5 for @entity3 .

answer: @entity4


abstract: OBJECTIVE: To evaluate the amount and type of @entity3 observed in chronic rhinosinusitis with @entity2 (CRSwNP) and compare it with that of chronic rhinosinusitis without @entity2 (CRSnNP). SETTING: Sisli Etfal Research and Education Hospital, Istanbul, @entity1 . STUDY DESIGN: Prospective, single-blind, cohort study. METHODS: Three different @entity0 groups, designated as the CRSwNP, CRSnNP, and control groups, were included in the study. Forty @entity0 who had CRSnNP and/or CRSwNP confirmed with a paranasal sinus computerized tomography (CT) study were included for the study group, and 20 individuals were included in the control group. Paranasal sinus CTs were evaluated and compared for @entity3 . RESULTS: Hounsfield units obtained from the right and left agger nasi walls and the medial maxillary sinus wall in the control group were significantly different from the entire group. Similarly, values for the anterior ethmoid wall were statistically significant for the CRSwNP group compared with all the subjects. When the groups were compared to one another, there were significant differences in both the right and left agger nasi walls and the frontal sinus wall. CONCLUSION: Differentiating and acknowledging @entity3 induced by CRSwNP rather than CRSnNP may aid in preoperative planning and indicate where to be more aggressive when excising bony structures. This may help in reducing recurrence and in increasing quality of life.

title: The radiologic evaluation of osteitis type and formation in chronic rhinosinusitis with and without XXXX .

answer: @entity2


abstract: OBJECTIVES: Health outcomes among older @entity3 ( @entity3 ) @entity0 may be influenced by physical, economic, and psychological problems not routinely identified during the @entity3 visit. The objective of this study was to characterize such problems among older adults presenting to the @entity3 . METHODS: This was a prevalence study with enrollment during 4-hour periods randomly selected between 9  a.m. and 9  p.m. on random  days of the week over a period of 8  weeks at an academic @entity3 in the southeast United States. @entity0 were noninstitutionalized, cognitively intact adults aged 65  years or older without life-threatening @entity1 . Consenting @entity0 were asked about the frequency of 10 prespecified problems during the past year. RESULTS: @entity0 (N  =  138) were non-Hispanic white (69%) and female (57%) and almost all had primary providers (95%) and health insurance (98%). Forty percent reported their overall health as fair (21%) or poor (19%). Hazardous drinking habits were reported by 10% of @entity0 . The prevalence of problems occurring either "sometimes" or "often" in the past year were @entity2 (60%), difficulty walking (47%), lack of money (32%), isolation and loneliness (14%), lack of transportation (12%), difficulty scheduling a doctor's appointment (4%), difficulty getting prescriptions filled (4%), and lack of dental care (6%). Nine @entity0 (7%) reported experiencing physical or @entity4 at some point in the past year. Females, minorities, and individuals living in urban areas reported higher rates of most problems. CONCLUSIONS: Nonmedical problems are common among cognitively intact, independent living, non-critically ill older @entity0 presenting to an @entity3 in the southeast United States.

title: Prevalence of nonmedical problems among older adults presenting to the XXXX .

answer: @entity3


abstract: BACKGROUND: Adalimumab is an effective treatment for @entity1 ( @entity1 ). Anti-adalimumab antibodies (AAA) and low trough serum drug concentrations have been implicated as pre-disposing factors for treatment failure. AIMS: To assess adalimumab and AAA serum levels, and to examine their association and discriminatory ability with clinical response and serum @entity2 ( @entity2 ). METHODS: We performed a cross-sectional study using trough sera from adalimumab-treated @entity1 @entity0 . Demographical data, Montreal classification, treatment regimen and clinical status were recorded. Serum adalimumab, AAA and @entity2 were measured. Receiver operating characteristic analysis and a multivariate regression model were performed to find drug and antibody thresholds for predicting disease activity at time of serum sampling. RESULTS: One hundred and eighteen trough serum samples were included from 71 @entity0 . High adalimumab trough serum concentration was associated with disease remission (Area Under Curve 0.748, P < 0.001). A cut-off drug level of 5.85  g/mL yielded optimal sensitivity, specificity and positive likelihood ratio for remission prediction (68%, 70.6% and 2.3, respectively). AAA were inversely related with adalimumab drug levels (Spearman's r = -0.411, P < 0.001) and when subdivided into categorical values, positively related with disease activity (P < 0.001). High drug levels and stricturing vs. penetrating or inflammatory phenotype, but not AAA levels, independently predicted disease remission in a multivariate logistic regression model. CONCLUSIONS: Adalimumab drug levels were inversely related to disease activity. High levels of anti-adalimumab antibodies were positively associated with disease activity, but this association was mediated mostly by adalimumab drug levels.

title: Adalimumab drug and antibody levels as predictors of clinical and laboratory response in @entity0 with XXXX .

answer: @entity1


abstract: BACKGROUND: Adalimumab is an effective treatment for @entity1 ( @entity1 ). Anti-adalimumab antibodies (AAA) and low trough serum drug concentrations have been implicated as pre-disposing factors for treatment failure. AIMS: To assess adalimumab and AAA serum levels, and to examine their association and discriminatory ability with clinical response and serum @entity2 ( @entity2 ). METHODS: We performed a cross-sectional study using trough sera from adalimumab-treated @entity1 @entity0 . Demographical data, Montreal classification, treatment regimen and clinical status were recorded. Serum adalimumab, AAA and @entity2 were measured. Receiver operating characteristic analysis and a multivariate regression model were performed to find drug and antibody thresholds for predicting disease activity at time of serum sampling. RESULTS: One hundred and eighteen trough serum samples were included from 71 @entity0 . High adalimumab trough serum concentration was associated with disease remission (Area Under Curve 0.748, P < 0.001). A cut-off drug level of 5.85  g/mL yielded optimal sensitivity, specificity and positive likelihood ratio for remission prediction (68%, 70.6% and 2.3, respectively). AAA were inversely related with adalimumab drug levels (Spearman's r = -0.411, P < 0.001) and when subdivided into categorical values, positively related with disease activity (P < 0.001). High drug levels and stricturing vs. penetrating or inflammatory phenotype, but not AAA levels, independently predicted disease remission in a multivariate logistic regression model. CONCLUSIONS: Adalimumab drug levels were inversely related to disease activity. High levels of anti-adalimumab antibodies were positively associated with disease activity, but this association was mediated mostly by adalimumab drug levels.

title: Adalimumab drug and antibody levels as predictors of clinical and laboratory response in XXXX with @entity1 .

answer: @entity0


abstract: The neurons of the medial terminal nucleus (MTN) of the @entity3 ( @entity3 ) have been studied in the @entity0 , @entity1 and cat in Golgi-Cox and Golgi-Kopsch impregnated brain sections. The present anatomical findings permit a division of the MTN of these species into dorsal and ventral components (MTNd, MTNv), in agreement with other investigations. The MTNd contains @entity2 neurons with cell bodies that measure in the range of 25-50 microns. These neurons have 2 to 4 primary dendrites which, along with their smaller dendritic branches, are oriented in the plane of the long axis of the MTN (i.e. from ventromedial to dorsolateral). These @entity2 represent 70-80% of the neurons of the MTNd as seen in the Golgi impregnated sections. The remaining 20-30% of the MTNd neurons are nearly all multipolar in shape with somata measuring in the range of 15-25 microns. An occasional multipolar neuron is larger, has a soma that measures around 30-60 microns and has dendrites which extend outward from the cell body to cover large areas of the MTNd. There was considerable extension of the dendrites of MTNd neurons into the MTNv; however, the dendrites of MTNd neurons were not observed extending into the adjacent substantia nigra (SN) or ventral tegmental area (VTA) of Tsai (1925). Conversely, the dendrites of neurons in the neighboring SN and VTA course along the borders of the MTN but only occasionally extend into the MTN.(ABSTRACT TRUNCATED AT 250 WORDS)

title: The dendritic architecture of the medial terminal nucleus of the XXXX in the @entity0 , @entity1 , and cat.

answer: @entity3


abstract: The neurons of the medial terminal nucleus (MTN) of the @entity3 ( @entity3 ) have been studied in the @entity0 , @entity1 and cat in Golgi-Cox and Golgi-Kopsch impregnated brain sections. The present anatomical findings permit a division of the MTN of these species into dorsal and ventral components (MTNd, MTNv), in agreement with other investigations. The MTNd contains @entity2 neurons with cell bodies that measure in the range of 25-50 microns. These neurons have 2 to 4 primary dendrites which, along with their smaller dendritic branches, are oriented in the plane of the long axis of the MTN (i.e. from ventromedial to dorsolateral). These @entity2 represent 70-80% of the neurons of the MTNd as seen in the Golgi impregnated sections. The remaining 20-30% of the MTNd neurons are nearly all multipolar in shape with somata measuring in the range of 15-25 microns. An occasional multipolar neuron is larger, has a soma that measures around 30-60 microns and has dendrites which extend outward from the cell body to cover large areas of the MTNd. There was considerable extension of the dendrites of MTNd neurons into the MTNv; however, the dendrites of MTNd neurons were not observed extending into the adjacent substantia nigra (SN) or ventral tegmental area (VTA) of Tsai (1925). Conversely, the dendrites of neurons in the neighboring SN and VTA course along the borders of the MTN but only occasionally extend into the MTN.(ABSTRACT TRUNCATED AT 250 WORDS)

title: The dendritic architecture of the medial terminal nucleus of the @entity3 in the @entity0 , XXXX , and cat.

answer: @entity1


abstract: The neurons of the medial terminal nucleus (MTN) of the @entity3 ( @entity3 ) have been studied in the @entity0 , @entity1 and cat in Golgi-Cox and Golgi-Kopsch impregnated brain sections. The present anatomical findings permit a division of the MTN of these species into dorsal and ventral components (MTNd, MTNv), in agreement with other investigations. The MTNd contains @entity2 neurons with cell bodies that measure in the range of 25-50 microns. These neurons have 2 to 4 primary dendrites which, along with their smaller dendritic branches, are oriented in the plane of the long axis of the MTN (i.e. from ventromedial to dorsolateral). These @entity2 represent 70-80% of the neurons of the MTNd as seen in the Golgi impregnated sections. The remaining 20-30% of the MTNd neurons are nearly all multipolar in shape with somata measuring in the range of 15-25 microns. An occasional multipolar neuron is larger, has a soma that measures around 30-60 microns and has dendrites which extend outward from the cell body to cover large areas of the MTNd. There was considerable extension of the dendrites of MTNd neurons into the MTNv; however, the dendrites of MTNd neurons were not observed extending into the adjacent substantia nigra (SN) or ventral tegmental area (VTA) of Tsai (1925). Conversely, the dendrites of neurons in the neighboring SN and VTA course along the borders of the MTN but only occasionally extend into the MTN.(ABSTRACT TRUNCATED AT 250 WORDS)

title: The dendritic architecture of the medial terminal nucleus of the @entity3 in the XXXX , @entity1 , and cat.

answer: @entity0


abstract: @entity3 ( @entity3 ) is a @entity2 of unknown etiology with @entity6 and @entity2 leading to @entity4 . It is considered to be a @entity1 with the interplay of both genetic and environmental factors. One of the possible genes implicated in @entity3 is @entity5 ( @entity5 ). The genetic variants of @entity5 may be involved in the pathophysiology of @entity3 hence the entire @entity5 gene was screened to examine for the possible genotypic associations with @entity3 . A total of 115 @entity3 @entity0 and 250 control subjects were included in the present study. PCR based SSCP analysis was carried out followed by commercial sequencing. Screening of @entity5 revealed two common and two rare polymorphisms. Allelic and genotypic frequencies were estimated in @entity0 and control groups by appropriate statistical tests. The heterozygotes of insertion variation (+138A) were found to exhibit four-fold increase risk to @entity3 (OR=4.12, 95% CI 2.10-8.08; p=0.0001). The two rare variants ( @entity8 transition ( @entity9 ) at c.90 and @entity7 transition ( @entity10 ) at c.119) observed in the present study were found to be unique in @entity3 . The secondary mRNA structures of these variations were found to have less free energy than wild type. The haplotype analysis revealed 4A-T to be risk haplotype for @entity3 (OR 5.90, 95% CI 2.29-15.25, p=0.0001). In conclusion, @entity5 polymorphisms (+138A, A30A, @entity11 ) appear to play a significant role in the pathogenesis of @entity3 , as they influence the stability of protein. The increased @entity5 production may lead to constriction of coronary arteries, reducing coronary blood flow which may in turn increase the load on left ventricle, impairing contractility of the heart resulting in a @entity3 phenotype, an end stage of @entity4 .

title: @entity5 gene as a modifier in dilated XXXX .

answer: @entity2


abstract: @entity3 ( @entity3 ) is a @entity2 of unknown etiology with @entity6 and @entity2 leading to @entity4 . It is considered to be a @entity1 with the interplay of both genetic and environmental factors. One of the possible genes implicated in @entity3 is @entity5 ( @entity5 ). The genetic variants of @entity5 may be involved in the pathophysiology of @entity3 hence the entire @entity5 gene was screened to examine for the possible genotypic associations with @entity3 . A total of 115 @entity3 @entity0 and 250 control subjects were included in the present study. PCR based SSCP analysis was carried out followed by commercial sequencing. Screening of @entity5 revealed two common and two rare polymorphisms. Allelic and genotypic frequencies were estimated in @entity0 and control groups by appropriate statistical tests. The heterozygotes of insertion variation (+138A) were found to exhibit four-fold increase risk to @entity3 (OR=4.12, 95% CI 2.10-8.08; p=0.0001). The two rare variants ( @entity8 transition ( @entity9 ) at c.90 and @entity7 transition ( @entity10 ) at c.119) observed in the present study were found to be unique in @entity3 . The secondary mRNA structures of these variations were found to have less free energy than wild type. The haplotype analysis revealed 4A-T to be risk haplotype for @entity3 (OR 5.90, 95% CI 2.29-15.25, p=0.0001). In conclusion, @entity5 polymorphisms (+138A, A30A, @entity11 ) appear to play a significant role in the pathogenesis of @entity3 , as they influence the stability of protein. The increased @entity5 production may lead to constriction of coronary arteries, reducing coronary blood flow which may in turn increase the load on left ventricle, impairing contractility of the heart resulting in a @entity3 phenotype, an end stage of @entity4 .

title: XXXX gene as a modifier in dilated @entity2 .

answer: @entity5


abstract: OBJECTIVE: To study analgesic possibilities of @entity4 . MATERIAL AND METHODS: A study included 120 @entity0 , aged from 40 to 65 years, with @entity3 . Duration of illness was not less than 12 weeks, the VAS score was >3. @entity0 were stratified into 4 groups (2 pairs of comparison). In the first pair, @entity0 of the main group (n=31) received a chondroprotector            with the addition of melaxen ( @entity4 in dose 3 mg) and @entity0 of the control group (n=29) received only           . In the second pair, @entity0 of the control group (n=30) were treated with            and @entity5 and @entity0 of the main group (n=30) received additionally melaxen. Treatment efficacy was assessed after 3 months for the first pair and after 1 month for the second pair. RESULTS: A significant reduction in @entity1 intensity at both resting state and movement was noted in main groups compared to controls. CONCLUSION: Due to its therapeutic efficacy and good tolerability, @entity4 may be regarded as a drug of choice in the complex treatment of @entity2 . Possible analgesic properties of @entity4 and their mechanisms are discussed.

title: [ XXXX and @entity1 ].

answer: @entity4


abstract: OBJECTIVE: To study analgesic possibilities of @entity4 . MATERIAL AND METHODS: A study included 120 @entity0 , aged from 40 to 65 years, with @entity3 . Duration of illness was not less than 12 weeks, the VAS score was >3. @entity0 were stratified into 4 groups (2 pairs of comparison). In the first pair, @entity0 of the main group (n=31) received a chondroprotector            with the addition of melaxen ( @entity4 in dose 3 mg) and @entity0 of the control group (n=29) received only           . In the second pair, @entity0 of the control group (n=30) were treated with            and @entity5 and @entity0 of the main group (n=30) received additionally melaxen. Treatment efficacy was assessed after 3 months for the first pair and after 1 month for the second pair. RESULTS: A significant reduction in @entity1 intensity at both resting state and movement was noted in main groups compared to controls. CONCLUSION: Due to its therapeutic efficacy and good tolerability, @entity4 may be regarded as a drug of choice in the complex treatment of @entity2 . Possible analgesic properties of @entity4 and their mechanisms are discussed.

title: [ @entity4 and XXXX ].

answer: @entity1


abstract: OBJECTIVE: Spontaneous spinal cerebrospinal fluid (CSF) leaks are rare (5 per 100,000 per year). Treatment generally consists of conservative therapy or interventional therapy with epidural blood patching. Surgical treatment is conducted rarely, usually in cases when conservative or interventional treatment has failed. The aim of our case series was to assess the clinical outcome after surgery. METHODS: Our clinical database was reviewed for @entity0 with spontaneous spinal CSF leaks who underwent surgical exploration between 2010 and 2013. Etiology, symptoms, preoperative imaging, type of required surgical method, intraoperative findings, and clinical outcome were reported. RESULTS: We identified five @entity0 with a mean age of 62  years with spontaneous spinal CSF leaks who were treated surgically. Two @entity0 received surgery after failure of interventional treatment. The origin of the CSF leak could be identified intraoperatively in three cases. Surgical technique in all cases consisted of an interlaminar fenestration or hemilaminectomy and a complete foraminotomy to explore the thecal sack and the exiting nerve roots and identify the CSF leak. After surgery, the preoperative symptoms improved in all @entity0 . In one case, there was a relapse after 4  weeks. CONCLUSIONS: Preoperative identification of a CSF leak with MRI was positive in only one case. In all other cases, a post-myelography CT had to be performed. In all cases, the preoperative symptoms improved after surgery. Surgical treatment is an effective treatment of spontaneous @entity1 in cases of refractory symptoms after failed conservative or interventional treatment.

title: Treatment strategy for cerebral hypotension caused by spontaneous XXXX .

answer: @entity1


abstract: BACKGROUND: To establish whether the current training of student sonographers in both academic and clinical settings is sufficient for educating about the dangers of @entity0 ( @entity0 ). METHODS: A dual method of data collection was undertaken. Initially, a focus group was set up, involving a small group of practicing sonographers from a hospital in the United Kingdom, with the results of that survey being used to design a postal survey questionnaire. The questionnaire focused on ergonomics, scanning technique, training in physical techniques, personal general health, risk, stress, and task management. It was sent to seven participating universities across the United Kingdom. Approvals were obtained from the local ethics committees, the hospital Trust, and the academic institution. RESULTS: The focus group highlighted several areas in which improvements could be made in educating sonographers on the reduction of @entity0 . The questionnaire results indicated that students are being taught about certain aspects of @entity1 prevention by both their university and clinical mentors. Respondents received training on the prevention of @entity0 : 97% in the university setting and 81% from clinical mentors. CONCLUSIONS: Improvements need to be made in terms of educating students to perform muscle-strengthening exercises during the workday; to have a system of reporting injury; to consider personal health, well-being, and stress management in the workplace; and to evaluate the ergonomics of computer workstations.    2014 Wiley Periodicals, Inc. J Clin Ultrasound, 2014;

title: Survey of UK sonographers on the prevention of @entity1 ( XXXX ).

answer: @entity1


abstract: BACKGROUND: To establish whether the current training of student sonographers in both academic and clinical settings is sufficient for educating about the dangers of @entity0 ( @entity0 ). METHODS: A dual method of data collection was undertaken. Initially, a focus group was set up, involving a small group of practicing sonographers from a hospital in the United Kingdom, with the results of that survey being used to design a postal survey questionnaire. The questionnaire focused on ergonomics, scanning technique, training in physical techniques, personal general health, risk, stress, and task management. It was sent to seven participating universities across the United Kingdom. Approvals were obtained from the local ethics committees, the hospital Trust, and the academic institution. RESULTS: The focus group highlighted several areas in which improvements could be made in educating sonographers on the reduction of @entity0 . The questionnaire results indicated that students are being taught about certain aspects of @entity1 prevention by both their university and clinical mentors. Respondents received training on the prevention of @entity0 : 97% in the university setting and 81% from clinical mentors. CONCLUSIONS: Improvements need to be made in terms of educating students to perform muscle-strengthening exercises during the workday; to have a system of reporting injury; to consider personal health, well-being, and stress management in the workplace; and to evaluate the ergonomics of computer workstations.    2014 Wiley Periodicals, Inc. J Clin Ultrasound, 2014;

title: Survey of UK sonographers on the prevention of XXXX ( @entity1 ).

answer: @entity1


abstract: BACKGROUNDS: The @entity0 of the dependent elderly require special attention. METHODS: This screening and treatment service of @entity0 was conducted in a Veterans Home in Southern Taiwan. RESULTS: A total of 337 male residents were screened with mean age 83  years (range 46-99). 271 (80.4  %) residents were in dependent status. Their @entity2 were recorded and the distribution pattern was compared with those in the other studies. Comparing by Chi-square test, scabies, @entity6 , chronic @entity3 , @entity1 , and @entity5 on the legs were present significantly in certain major systemic diseases, respectively. Higher prevalence of certain @entity2 was related to the severity of disability or major systemic diseases of the residents. @entity7 and @entity4 were early detected and managed. CONCLUSIONS: The distribution patterns of @entity2 in a Veterans Home were unique. It provides the evidences on appropriate management and key nursing points for dependent elderly.

title: A survey of XXXX among older male adults of a Veterans Home in Southern Taiwan.

answer: @entity0


abstract: BACKGROUND: The aim of this article is to present the functional results and the effect on quality of life of surgically treated @entity1 in physically active and working @entity0 with multiple and serious injuries. In addition, the relationships between functional and radiological outcome were evaluated and compared with activity in daily and professional life. @entity0 AND METHODS: In all, 41 injured @entity0 were followed up a mean of 47  months after surgical treatment and examined with radiological, functional, as well as quality of life score. RESULTS: In the radiological scoring, a mean value of 72  points (max 100  points) was achieved. In the activity score, there was an average of 63.5  points (max 100  points). When evaluating the health-related quality of life, an average score of 69.6  points was achieved. There was a significant relationship between radiological and activity scores and the radiological and life quality scores. Furthermore, the relationship between activity and quality of life scores was considered significant. Surgeon's influence on the functional outcome could be confirmed. CONCLUSION: The functional and the radiological results were moderate. Quality of life was permanently affected by the consequences of @entity1 in 12  @entity0 ; 11  @entity0 were not re-employed. However, the quality of life was assessed as good or very good and 28 @entity0 had returned to work. The quality of life was firmly linked to the radiological and functional parameters, which tended to be influenced by the quality of the primary surgical treatment when looking at the overall population.

title: [Quality of life and job performance resulting from operatively treated XXXX .]

answer: @entity1


abstract: PURPOSE: @entity3 ( @entity3 ) includes @entity4 ( @entity4 ) and @entity3 ( @entity3 ). They have different biological behavior but are frequently analyzed together in studies. We aimed to identify factors associated with mortality in those two different @entity2 subtypes. METHODS: Case series study, with clinical-pathological analysis of the characteristics of 424 @entity0 with @entity4 and 89 @entity0 with @entity3 , correlating them to survival rates in a single institution. RESULTS: @entity0 were followed from 1983 to 2011. Mean follow-up time was 9.4  years for @entity3 (range 1-36.6  years) and 6.8  years for @entity4 (range 1.1-30.7  years). Mean age at diagnosis was 51.2      15.5 for @entity3 and 41      14.7  years for @entity4 . 50.62  % of @entity3 nodules sized 1.1-4  cm and 20  % of @entity4 sized  <=1  cm. Cox multiple regression analysis evidenced distant @entity1 at diagnosis (p  =  0.0038; relative risk (RR) 41.247, 95  % confidence interval (CI) 3.317-512.986), lymph node @entity1 at diagnosis (p  =  0.0081; RR 50.98, 95  % CI 2.783-934.026) and vascular/lymphatic invasion (p  =  0.0039; RR 40.424, 95  % CI 3.287-497.177) as factors related to mortality in @entity3 @entity0 . For @entity4 , the factors were distant @entity1 at diagnosis (p  <  0.0001; RR 32.5, 95  % CI 6.676-158.543) and degree of differentiation (poor versus well differentiated, p  =  0.003; RR 10.4, 95  % CI 2.218-49.487). CONCLUSION: The common factor that influenced mortality for @entity3 and @entity4 @entity0 was distant @entity1 at diagnosis, increasing mortality rate by 41 times in @entity3 and 30 times in @entity4 @entity0 . The different factors influencing mortality for different @entity3 types highlight the importance of analyzing them separately.

title: Factors related to mortality in @entity0 with XXXX in long-term follow-up.

answer: @entity4


abstract: PURPOSE: @entity3 ( @entity3 ) includes @entity4 ( @entity4 ) and @entity3 ( @entity3 ). They have different biological behavior but are frequently analyzed together in studies. We aimed to identify factors associated with mortality in those two different @entity2 subtypes. METHODS: Case series study, with clinical-pathological analysis of the characteristics of 424 @entity0 with @entity4 and 89 @entity0 with @entity3 , correlating them to survival rates in a single institution. RESULTS: @entity0 were followed from 1983 to 2011. Mean follow-up time was 9.4  years for @entity3 (range 1-36.6  years) and 6.8  years for @entity4 (range 1.1-30.7  years). Mean age at diagnosis was 51.2      15.5 for @entity3 and 41      14.7  years for @entity4 . 50.62  % of @entity3 nodules sized 1.1-4  cm and 20  % of @entity4 sized  <=1  cm. Cox multiple regression analysis evidenced distant @entity1 at diagnosis (p  =  0.0038; relative risk (RR) 41.247, 95  % confidence interval (CI) 3.317-512.986), lymph node @entity1 at diagnosis (p  =  0.0081; RR 50.98, 95  % CI 2.783-934.026) and vascular/lymphatic invasion (p  =  0.0039; RR 40.424, 95  % CI 3.287-497.177) as factors related to mortality in @entity3 @entity0 . For @entity4 , the factors were distant @entity1 at diagnosis (p  <  0.0001; RR 32.5, 95  % CI 6.676-158.543) and degree of differentiation (poor versus well differentiated, p  =  0.003; RR 10.4, 95  % CI 2.218-49.487). CONCLUSION: The common factor that influenced mortality for @entity3 and @entity4 @entity0 was distant @entity1 at diagnosis, increasing mortality rate by 41 times in @entity3 and 30 times in @entity4 @entity0 . The different factors influencing mortality for different @entity3 types highlight the importance of analyzing them separately.

title: Factors related to mortality in XXXX with @entity4 in long-term follow-up.

answer: @entity0


abstract: BACKGROUND: Concussion and sports-related cranial and spine injuries recently have garnered increased attention from the media, public, and sports' governing bodies. Although concussion has been well-studied, there are minimal data on return to play for structural @entity1 . OBJECTIVE: We aimed to study current neurosurgical practice on return to play for structural @entity1 in order to eventually establish guidelines for these athletes. METHODS: A survey was sent to all American Association of Neurological Surgeons members inviting them to submit information on athletes who presented with structural @entity1 . These included both operative and nonoperative lesions. Ten examples of relevant clinical scenarios were included. Neurosurgeons were surveyed about their practice of clearing these @entity0 for return to play and about @entity0 outcomes afterwards, including any clinical sequelae. Responses were tabulated and studied to search for trends in current practice. Nonstructural cases, such as concussion and cervical strain cases, were excluded. The Mann-Whitney U test was used to test for statistical difference in the time to return for spine versus cranial, instrumented versus noninstrumented spine, and pediatric versus adult cases. RESULTS: Ninety-eight respondents entered data on a total of 189 @entity0 (118 surgical and 71 nonoperative/incidental). In the surgical category, 109 cases (41 cranial, 67 spine, and 1 @entity2 ) met inclusion criteria. There was a significant difference in time to return between spine (88% returned  <=6 months) versus cranial (50% returned >6 months, P < 0.001), noninstrumented (55% returned  <=3 months) versus instrumented spine (92% returned >3 months, P  = 0.001), and adult (78% returned  <=6 months) versus pediatric cases (52% returned >6 months, P  = 0.021). Fifty nonoperative/incidental cases met inclusion criteria; 94% of athletes returning to play with nonoperative lesions had no reported clinical sequelae. All nonsurgical and 81% of surgical respondents required deficit resolution before return to play. CONCLUSIONS: The results presented here are the first effort to study current practice on return to play for structural @entity1 . They establish an early foundation for neurosurgical guidelines on these @entity0 .

title: Return to Play for Neurosurgical XXXX .

answer: @entity0


abstract: PURPOSE: @entity2 ( @entity2 ) is suggested to be effective in rehabilitation training, but more knowledge is required about its potential muscle damaging effects. Therefore, we investigated muscle-damaging effects of @entity2 performed to failure and possible protective effects of previous bouts of @entity2 or maximal eccentric exercise (ECC). METHODS: Seventeen healthy young @entity0 were allocated into two groups completing two exercise bouts separated by 14  days. One group performed @entity2 in both exercise bouts (BB). The other group performed ECC in the first and @entity2 in the second bout. @entity2 was performed to failure. Indicators of @entity1 were evaluated before and after exercise. RESULTS: The first bout in the BB group led to decrements in maximum isometric torque, and increases in muscle soreness, muscle water retention, and serum muscle protein concentrations after exercise. These changes were comparable in magnitude and time course to what was observed after first bout ECC. An attenuated response was observed in the repeated exercise bout in both groups. CONCLUSION: We conclude that unaccustomed single-bout @entity2 performed to failure induces significant @entity1 . Additionally, both ECC and @entity2 can precondition against @entity1 induced by a subsequent bout of @entity2 .

title: XXXX and repeated bout effect following blood flow restricted exercise.

answer: @entity1


abstract: @entity10 (MTs) are a rare group of @entity2 showing predominant or exclusive myoepithelial differentiation. They are poorly characterized from both a morphologic and genetic standpoint, in particular features that separate benign from malignant behavior. We examined the histologic and immunohistochemical features of 8 primary thoracic MTs and performed fluorescence in situ hybridization for @entity7 , @entity9 , @entity12 , and @entity6 , as well as several partner genes. Half (4/8) of the MTs occurred in large airways, and 3 had infiltrative borders. All cases showed immunoreactivity for epithelial markers, in conjunction with @entity5 protein or myogenic markers. MTs showed morphologic characteristics analogous to MTs at other sites, with no @entity2 having ductal differentiation. @entity3 and/or lymphovascular invasion was present in 5 cases, with mitotic activity ranging from 0 to 6 mitoses/2 mm (mean 1). @entity1 occurred in 2 cases, and no @entity0 died of disease. Gene rearrangements were identified in half of the cases, with @entity7 - @entity11 , @entity7 - @entity13 , and @entity9 - @entity8 fusions identified in 1 case each and 1 case having @entity7 rearrangement with no partner identified. No cases were found to have @entity6 or @entity12 abnormalities. Compared with fusion-negative @entity2 , fusion-positive @entity2 tended to occur in @entity0 who were younger (50 vs. 58 y), female (1:3 vs. 3:1 male:female ratio), and demonstrated predominantly spindle and clear cell morphology. Using a combined data set of our case series with 16 cases from the literature, poor prognosis was significantly correlated with @entity1 (P=0.003), @entity3 (P=0.027), and >= 5 mitoses/2 mm/10 high-power field (P=0.005). In summary, we identify a subset of thoracic MTs harboring rearrangements in @entity7 or @entity9 , and our data suggest that @entity3 and increased mitotic activity correlate with @entity4 clinical behavior.

title: XXXX : A Pathologic and Molecular Study of 8 Cases With Review of the Literature.

answer: @entity10


abstract: BACKGROUND: @entity1 ( @entity1 ) and @entity2 ( @entity2 ) share many overlapping clinical features, confounding the current diagnostic systems. Recent studies suggest the posterior cingulate ( @entity3 ) and medial prefrontal (MPFC) cortices that are involved in @entity1 and @entity2 pathophysiology. However, the roles of @entity3 and MPFC in providing specific distinctive and shared neural substrates between these two disorders remain largely unknown. Examining the neurophysiologic mechanism of these diseases may help explain the clinical observations and differentiate the two disorders. METHODS: We used the Dynamic Casual Modeling (DCM), which is capable of eliciting hidden neuronal dynamics and reveal cross-regulation of multiple neuronal systems, to characterize the pattern of disrupted effective connectivity in the left @entity3 -MPFC circuit during working memory tasks in 36 @entity1 and 20 @entity2 @entity0 as well as 29 healthy controls. RESULTS: Compared to the healthy controls, both @entity1 and @entity2 @entity0 groups exhibited significant negative effective connectivity from the left MPFC to @entity3 . The negative effective connectivity was more remarkable in @entity1 @entity0 . Only @entity0 with @entity2 differed from healthy controls with positive effective connectivity from the left @entity3 to MPFC. CONCLUSIONS: Whole brain analysis revealed deactivation of the left @entity3 and MPFC across all @entity0 groups. This study provides new insight that changes in effective connectivity of the left MPFC to left @entity3 circuit during working memory processing may be a core pathophysiological feature distinguishing @entity1 from @entity2 .

title: Effective connectivity of the posterior cingulate and medial prefrontal cortices relates to working memory impairment in @entity1 and XXXX @entity0 .

answer: @entity2


abstract: BACKGROUND: @entity1 ( @entity1 ) and @entity2 ( @entity2 ) share many overlapping clinical features, confounding the current diagnostic systems. Recent studies suggest the posterior cingulate ( @entity3 ) and medial prefrontal (MPFC) cortices that are involved in @entity1 and @entity2 pathophysiology. However, the roles of @entity3 and MPFC in providing specific distinctive and shared neural substrates between these two disorders remain largely unknown. Examining the neurophysiologic mechanism of these diseases may help explain the clinical observations and differentiate the two disorders. METHODS: We used the Dynamic Casual Modeling (DCM), which is capable of eliciting hidden neuronal dynamics and reveal cross-regulation of multiple neuronal systems, to characterize the pattern of disrupted effective connectivity in the left @entity3 -MPFC circuit during working memory tasks in 36 @entity1 and 20 @entity2 @entity0 as well as 29 healthy controls. RESULTS: Compared to the healthy controls, both @entity1 and @entity2 @entity0 groups exhibited significant negative effective connectivity from the left MPFC to @entity3 . The negative effective connectivity was more remarkable in @entity1 @entity0 . Only @entity0 with @entity2 differed from healthy controls with positive effective connectivity from the left @entity3 to MPFC. CONCLUSIONS: Whole brain analysis revealed deactivation of the left @entity3 and MPFC across all @entity0 groups. This study provides new insight that changes in effective connectivity of the left MPFC to left @entity3 circuit during working memory processing may be a core pathophysiological feature distinguishing @entity1 from @entity2 .

title: Effective connectivity of the posterior cingulate and medial prefrontal cortices relates to working memory impairment in XXXX and @entity2 @entity0 .

answer: @entity1


abstract: BACKGROUND: @entity1 ( @entity1 ) and @entity2 ( @entity2 ) share many overlapping clinical features, confounding the current diagnostic systems. Recent studies suggest the posterior cingulate ( @entity3 ) and medial prefrontal (MPFC) cortices that are involved in @entity1 and @entity2 pathophysiology. However, the roles of @entity3 and MPFC in providing specific distinctive and shared neural substrates between these two disorders remain largely unknown. Examining the neurophysiologic mechanism of these diseases may help explain the clinical observations and differentiate the two disorders. METHODS: We used the Dynamic Casual Modeling (DCM), which is capable of eliciting hidden neuronal dynamics and reveal cross-regulation of multiple neuronal systems, to characterize the pattern of disrupted effective connectivity in the left @entity3 -MPFC circuit during working memory tasks in 36 @entity1 and 20 @entity2 @entity0 as well as 29 healthy controls. RESULTS: Compared to the healthy controls, both @entity1 and @entity2 @entity0 groups exhibited significant negative effective connectivity from the left MPFC to @entity3 . The negative effective connectivity was more remarkable in @entity1 @entity0 . Only @entity0 with @entity2 differed from healthy controls with positive effective connectivity from the left @entity3 to MPFC. CONCLUSIONS: Whole brain analysis revealed deactivation of the left @entity3 and MPFC across all @entity0 groups. This study provides new insight that changes in effective connectivity of the left MPFC to left @entity3 circuit during working memory processing may be a core pathophysiological feature distinguishing @entity1 from @entity2 .

title: Effective connectivity of the posterior cingulate and medial prefrontal cortices relates to working memory impairment in @entity1 and @entity2 XXXX .

answer: @entity0


abstract: BACKGROUND: @entity1 ( @entity1 ) and @entity3 ( @entity3 ) are prevalent in the elderly and are associated with significant morbidity and mortality. The main objectives of this study were to examine the relative impact and joint association of @entity1 and @entity3 with @entity2 , @entity0 and all-cause mortality, and their impact on risk classification using a continuous net reclassification index. METHODS AND RESULTS: We followed 2342 adults without prevalent @entity0 (mean age, 76 years) from the @entity0 for a median of 12.6 years. @entity3 was defined as LV ejection fraction <55%. @entity1 was defined as: forced expiratory volume in 1 second:forced vital capacity <70%, and predicted forced expiratory volume in 1 second <80%. Outcomes included @entity2 hospitalization, @entity0 , all-cause mortality, and composite outcome. @entity3 was detected in 128 subjects (6%), @entity1 in 441 (19%) and both in 38 (2%). Compared to those without @entity3 or @entity1 , there was a significantly increased cardiovascular risk for groups of @entity3 only, @entity1 only, and @entity3 plus @entity1 , adjusted hazard ratio (95% CI) 2.1 (1.5-3.0), 1.7 (1.4-2.1), and 3.2 (2.0-5.1) for HF; 1.8 (1.2-2.6), 1.4 (1.1-1.8), and 2.8 (1.7-4.7) for @entity0 ; 1.3 (1.0-1.8), 1.7 (1.4-1.9), and 2.1 (1.5-3.0) for all-cause mortality, and 1.6 (1.3-2.1), 1.7 (1.5-1.9), and 2.4 (1.7-3.3) for composite outcome, respectively. Risk classification improved significantly for all outcomes when @entity1 was added to the adjusted model with @entity3 or @entity3 to @entity1 . CONCLUSIONS: While risk of cardiovascular outcomes was the highest among elderly with both @entity3 and @entity1 , risk was comparable between subjects with @entity1 alone and those with @entity3 alone. This observation, combined with improved risk classification by adding @entity1 to @entity3 or @entity3 to @entity1 , underscore the importance of comprehensive heart and lung evaluation in cardiovascular outcome assessment.

title: Cardiovascular and Mortality Outcomes in the Elderly With Impaired Cardiac and Pulmonary Function: The XXXX ( @entity0 ).

answer: @entity0


abstract: BACKGROUND: @entity1 ( @entity1 ) and @entity3 ( @entity3 ) are prevalent in the elderly and are associated with significant morbidity and mortality. The main objectives of this study were to examine the relative impact and joint association of @entity1 and @entity3 with @entity2 , @entity0 and all-cause mortality, and their impact on risk classification using a continuous net reclassification index. METHODS AND RESULTS: We followed 2342 adults without prevalent @entity0 (mean age, 76 years) from the @entity0 for a median of 12.6 years. @entity3 was defined as LV ejection fraction <55%. @entity1 was defined as: forced expiratory volume in 1 second:forced vital capacity <70%, and predicted forced expiratory volume in 1 second <80%. Outcomes included @entity2 hospitalization, @entity0 , all-cause mortality, and composite outcome. @entity3 was detected in 128 subjects (6%), @entity1 in 441 (19%) and both in 38 (2%). Compared to those without @entity3 or @entity1 , there was a significantly increased cardiovascular risk for groups of @entity3 only, @entity1 only, and @entity3 plus @entity1 , adjusted hazard ratio (95% CI) 2.1 (1.5-3.0), 1.7 (1.4-2.1), and 3.2 (2.0-5.1) for HF; 1.8 (1.2-2.6), 1.4 (1.1-1.8), and 2.8 (1.7-4.7) for @entity0 ; 1.3 (1.0-1.8), 1.7 (1.4-1.9), and 2.1 (1.5-3.0) for all-cause mortality, and 1.6 (1.3-2.1), 1.7 (1.5-1.9), and 2.4 (1.7-3.3) for composite outcome, respectively. Risk classification improved significantly for all outcomes when @entity1 was added to the adjusted model with @entity3 or @entity3 to @entity1 . CONCLUSIONS: While risk of cardiovascular outcomes was the highest among elderly with both @entity3 and @entity1 , risk was comparable between subjects with @entity1 alone and those with @entity3 alone. This observation, combined with improved risk classification by adding @entity1 to @entity3 or @entity3 to @entity1 , underscore the importance of comprehensive heart and lung evaluation in cardiovascular outcome assessment.

title: Cardiovascular and Mortality Outcomes in the Elderly With Impaired Cardiac and Pulmonary Function: The @entity0 ( XXXX ).

answer: @entity0


abstract: INTRODUCTION: Interleukin (IL)-17 expression has been detected in @entity4 , but its role in the disease process remains unclear. The present study compared the expression of @entity5 in @entity2 and @entity3 and evaluated the association of this cytokine with clinical and radiographic findings. METHODS: @entity4 (18 cysts and 20 @entity3 ) were obtained from 38 @entity0 subjected to periradicular surgery. Some clinical, radiographic, and cone-beam computed tomographic features were recorded. Silanized slides containing paraffin sections were used for the immunohistochemical reactions using anti- @entity5 antibody. Image analysis was performed using an optical microscope, and each sample was divided into 5 high-power fields, which were evaluated for the expression of @entity5 in the epithelium and connective tissues. Results were evaluated for correlations with the lesion size and the occurrence of symptoms and sinus tract. RESULTS: Expression of @entity5 was significantly higher in cysts than in @entity3 (P = .02). Among the @entity2 , a thin epithelium showed significantly increased labeling for @entity5 when compared with a hyperplastic epithelium (P = .003). @entity5 expression was usually associated with focal accumulations of polymorphonuclear leukocytes. No association of @entity5 expression with symptoms, sinus tract, or lesion size was observed (P > .05). CONCLUSIONS: The present study reinforces the notion that @entity5 may take part in the pathogenesis of @entity4 . A role in the exacerbation of @entity1 and cyst formation is suspected. Further studies are required to shed light on the specific functions of @entity5 in periradicular inflammatory processes.

title: Immunoexpression of interleukin 17 in XXXX .

answer: @entity4


abstract: @entity6 ( @entity6 ), the accumulation of lipid within hepatocytes, is increasing in prevalence. Increasing @entity4 consumption correlates with this increased prevalence, and rodent studies directly support @entity4 leading to @entity6 . The mechanisms of @entity6 and in particular @entity4 -induced lipid accumulation remain unclear, although there is evidence for a role for endoplasmic reticulum (ER) stress and oxidative stress. We have evidence that @entity6 models demonstrate activation of the target of @entity10 complex 1 ( @entity11 ) pathway. We set out to assess the contribution of ER stress, oxidative stress, and @entity11 up-regulation in the development of @entity5 in @entity4 -treated larval @entity9 . @entity9 were treated with @entity4 or @entity3 as a calorie-matched control. We also treated larvae with @entity10 , @entity8 (ER stress), or @entity12 (oxidative stress). Fish were stained with oil red O to assess @entity2 , and we also performed quantitative polymerase chain reaction (qPCR)and western blot analysis. We performed immunostaining on samples from @entity0 with @entity6 and @entity6 ( @entity6 ). Treatment with @entity4 induced @entity2 , @entity7 , and ER defects. In addition, @entity4 -treated fish showed activation of inflammatory and lipogenic genes. Treatment with @entity8 or @entity12 also induced @entity2 . Expression microarray studies of @entity9 @entity6 models showed an elevation of genes downstream of @entity11 signaling. @entity10 treatment of @entity4 -treated fish prevented development of @entity5 , as did treatment of @entity8 - or @entity12 -treated fish. Examination of liver samples from @entity0 with @entity5 demonstrated activation of @entity11 signaling. CONCLUSION: @entity4 treatment of larval @entity9 induces @entity2 , @entity1 , and oxidative stress. Our results indicate that @entity11 activation is required for @entity2 across models of @entity6 , and in @entity0 . (Hepatology 2014;60:1581-1592).

title: @entity4 leads to XXXX in @entity9 that is reversed by mechanistic target of @entity10 (mTOR) inhibition.

answer: @entity5


abstract: @entity6 ( @entity6 ), the accumulation of lipid within hepatocytes, is increasing in prevalence. Increasing @entity4 consumption correlates with this increased prevalence, and rodent studies directly support @entity4 leading to @entity6 . The mechanisms of @entity6 and in particular @entity4 -induced lipid accumulation remain unclear, although there is evidence for a role for endoplasmic reticulum (ER) stress and oxidative stress. We have evidence that @entity6 models demonstrate activation of the target of @entity10 complex 1 ( @entity11 ) pathway. We set out to assess the contribution of ER stress, oxidative stress, and @entity11 up-regulation in the development of @entity5 in @entity4 -treated larval @entity9 . @entity9 were treated with @entity4 or @entity3 as a calorie-matched control. We also treated larvae with @entity10 , @entity8 (ER stress), or @entity12 (oxidative stress). Fish were stained with oil red O to assess @entity2 , and we also performed quantitative polymerase chain reaction (qPCR)and western blot analysis. We performed immunostaining on samples from @entity0 with @entity6 and @entity6 ( @entity6 ). Treatment with @entity4 induced @entity2 , @entity7 , and ER defects. In addition, @entity4 -treated fish showed activation of inflammatory and lipogenic genes. Treatment with @entity8 or @entity12 also induced @entity2 . Expression microarray studies of @entity9 @entity6 models showed an elevation of genes downstream of @entity11 signaling. @entity10 treatment of @entity4 -treated fish prevented development of @entity5 , as did treatment of @entity8 - or @entity12 -treated fish. Examination of liver samples from @entity0 with @entity5 demonstrated activation of @entity11 signaling. CONCLUSION: @entity4 treatment of larval @entity9 induces @entity2 , @entity1 , and oxidative stress. Our results indicate that @entity11 activation is required for @entity2 across models of @entity6 , and in @entity0 . (Hepatology 2014;60:1581-1592).

title: @entity4 leads to @entity5 in XXXX that is reversed by mechanistic target of @entity10 (mTOR) inhibition.

answer: @entity9


abstract: @entity6 ( @entity6 ), the accumulation of lipid within hepatocytes, is increasing in prevalence. Increasing @entity4 consumption correlates with this increased prevalence, and rodent studies directly support @entity4 leading to @entity6 . The mechanisms of @entity6 and in particular @entity4 -induced lipid accumulation remain unclear, although there is evidence for a role for endoplasmic reticulum (ER) stress and oxidative stress. We have evidence that @entity6 models demonstrate activation of the target of @entity10 complex 1 ( @entity11 ) pathway. We set out to assess the contribution of ER stress, oxidative stress, and @entity11 up-regulation in the development of @entity5 in @entity4 -treated larval @entity9 . @entity9 were treated with @entity4 or @entity3 as a calorie-matched control. We also treated larvae with @entity10 , @entity8 (ER stress), or @entity12 (oxidative stress). Fish were stained with oil red O to assess @entity2 , and we also performed quantitative polymerase chain reaction (qPCR)and western blot analysis. We performed immunostaining on samples from @entity0 with @entity6 and @entity6 ( @entity6 ). Treatment with @entity4 induced @entity2 , @entity7 , and ER defects. In addition, @entity4 -treated fish showed activation of inflammatory and lipogenic genes. Treatment with @entity8 or @entity12 also induced @entity2 . Expression microarray studies of @entity9 @entity6 models showed an elevation of genes downstream of @entity11 signaling. @entity10 treatment of @entity4 -treated fish prevented development of @entity5 , as did treatment of @entity8 - or @entity12 -treated fish. Examination of liver samples from @entity0 with @entity5 demonstrated activation of @entity11 signaling. CONCLUSION: @entity4 treatment of larval @entity9 induces @entity2 , @entity1 , and oxidative stress. Our results indicate that @entity11 activation is required for @entity2 across models of @entity6 , and in @entity0 . (Hepatology 2014;60:1581-1592).

title: @entity4 leads to @entity5 in @entity9 that is reversed by mechanistic target of XXXX (mTOR) inhibition.

answer: @entity10


abstract: @entity6 ( @entity6 ), the accumulation of lipid within hepatocytes, is increasing in prevalence. Increasing @entity4 consumption correlates with this increased prevalence, and rodent studies directly support @entity4 leading to @entity6 . The mechanisms of @entity6 and in particular @entity4 -induced lipid accumulation remain unclear, although there is evidence for a role for endoplasmic reticulum (ER) stress and oxidative stress. We have evidence that @entity6 models demonstrate activation of the target of @entity10 complex 1 ( @entity11 ) pathway. We set out to assess the contribution of ER stress, oxidative stress, and @entity11 up-regulation in the development of @entity5 in @entity4 -treated larval @entity9 . @entity9 were treated with @entity4 or @entity3 as a calorie-matched control. We also treated larvae with @entity10 , @entity8 (ER stress), or @entity12 (oxidative stress). Fish were stained with oil red O to assess @entity2 , and we also performed quantitative polymerase chain reaction (qPCR)and western blot analysis. We performed immunostaining on samples from @entity0 with @entity6 and @entity6 ( @entity6 ). Treatment with @entity4 induced @entity2 , @entity7 , and ER defects. In addition, @entity4 -treated fish showed activation of inflammatory and lipogenic genes. Treatment with @entity8 or @entity12 also induced @entity2 . Expression microarray studies of @entity9 @entity6 models showed an elevation of genes downstream of @entity11 signaling. @entity10 treatment of @entity4 -treated fish prevented development of @entity5 , as did treatment of @entity8 - or @entity12 -treated fish. Examination of liver samples from @entity0 with @entity5 demonstrated activation of @entity11 signaling. CONCLUSION: @entity4 treatment of larval @entity9 induces @entity2 , @entity1 , and oxidative stress. Our results indicate that @entity11 activation is required for @entity2 across models of @entity6 , and in @entity0 . (Hepatology 2014;60:1581-1592).

title: XXXX leads to @entity5 in @entity9 that is reversed by mechanistic target of @entity10 (mTOR) inhibition.

answer: @entity4


abstract: BACKGROUND: The receptor for advanced glycation end products ( @entity5 ) is recognized to be responsible for @entity1 progression in several @entity0 @entity1 . In this study, we investigated the clinical impact of @entity5 expression in @entity0 with @entity3 ( @entity3 ) after hepatectomy. MATERIALS AND METHODS: Sixty-five consecutive @entity0 who underwent initial hepatectomy for @entity3 were investigated. The relationships between immunohistochemical expression of @entity5 and clinicopathologic features, clinical outcome ( @entity4 [ @entity4 ], and @entity2 [ @entity2 ]) were evaluated. RESULTS: The cytoplasmic expression of @entity5 in @entity3 cells was observed in 46 @entity0 (70.8%) and correlated with histologic grade (poorly differentiated versus moderately differentiated @entity3 , P  =  0.021). Five-year @entity4 in @entity5 -positive and @entity5 -negative groups were 72% and 94%, respectively, whereas 5-y @entity2 were 29% and 55%, respectively. There were significant differences between @entity4 and @entity2 (P  =  0.018 and 0.031, respectively). Multivariate analysis indicated that @entity5 was an independent predictor for both @entity4 and @entity2 (P  =  0.048 and 0.032, respectively). CONCLUSIONS: Our data suggest for the first time a positive correlation between @entity5 expression and poor therapeutic outcome. Furthermore, @entity5 downregulation may provide a novel therapeutic target for @entity3 .

title: Prognostic significance of receptor for advanced glycation end products expression in XXXX after hepatectomy.

answer: @entity3